TE-8105: What a 38-Person First-in-Human Long-Acting GLP-1 Trial Actually Shows

TE-8105 showed an approximately 120-hour half-life and an expected gastrointestinal adverse-event pattern in a small first-in-human study. That is useful early pharmacology evidence—not proof that the investigational GLP-1 receptor agonist produces superior weight loss, is safer, improves adherence, or offers greater convenience than existing medicines.

The 2026 Journal of Clinical Pharmacology study enrolled 38 adults with overweight or obesity but without type 2 diabetes. It was open-label, had no placebo or active comparator, and was designed mainly to examine pharmacokinetics, preliminary pharmacodynamics, safety, and tolerability during dose escalation.[^paper]

A long half-life can justify further study of less-frequent administration, but a small first-in-human cohort leaves most questions about clinical benefit and long-term safety unanswered. Conceptual illustration; not a molecular model or trial result.

Quick facts about the TE-8105 GLP-1 study

• Compound: TE-8105, an investigational long-acting GLP-1 receptor agonist
• Registration: NCT06471530
• Design: Industry-funded, single-site, open-label, first-in-human Phase 1 study
• Participants: 38 medically screened adults with overweight or obesity but without type 2 diabetes
• Cohorts: 24 people in four single-ascending-dose cohorts; 14 in two multiple-dose cohorts
• Main pharmacokinetic finding: Approximately 120-hour terminal half-life
• Preliminary weight observation: In the eight-person titration cohort, mean end-of-study weight change was -2.06%; four maintained at least 5% loss
• Main limitation: No placebo or active comparator, with very small cohorts and limited follow-up

The registry describes the broader protocol as Phase 1/2a, while the published report presents these completed findings as the first-in-human Phase 1 study.[^registry] That distinction matters: this paper reports an early portion of a development program, not evidence from a large confirmatory trial.

What is TE-8105?

TE-8105 is an experimental GLP-1 receptor agonist engineered to remain in circulation for an extended period. The molecule includes a GLP-1 analog, a peptide linker, and a fatty-acid bundle intended to increase binding to serum albumin and slow clearance.

GLP-1 receptor agonism is an established drug mechanism, but a familiar mechanism does not transfer the evidence package of an approved medicine to a new molecule. TE-8105 still needs its own evidence on manufacturing quality, exposure, clinical outcomes, adverse effects, and use in broader populations. This is why GLP-1 peptides and research peptides should not be treated as interchangeable.

Quick answer: Is TE-8105 approved? No. TE-8105 is investigational. “Safe and well tolerated” in this early paper is the authors’ description of what happened in a small study; it is not regulatory approval or established clinical value.

What does the roughly 120-hour half-life mean?

A roughly 120-hour half-life means the measured plasma concentration declined slowly enough that the authors believe less-frequent subcutaneous administration may be feasible to study. Half-life is a pharmacokinetic measure: the estimated time required for plasma concentration to fall by half during the terminal elimination phase.

It does not tell us, by itself, whether a drug:

• produces more weight loss;
• controls appetite or glucose better;
• causes fewer adverse effects;
• improves real-world adherence;
• feels more convenient to patients; or
• has a better benefit-risk balance.

A longer-lasting exposure can be useful, but it can also raise questions about accumulation, reversibility, and how long adverse effects persist. Those questions require purpose-built clinical data. The paper reported different accumulation behavior across its two multiple-dose cohorts and noted atypical exposure behavior that requires further investigation.

Quick answer: Does a long half-life prove convenience? No. It supports testing a less-frequent schedule. Convenience and adherence are human outcomes that require comparative evidence, not a concentration-time curve.

Does the study show that TE-8105 causes meaningful weight loss?

No reliable efficacy conclusion can be drawn from the weight observations because the study was small, open-label, and uncontrolled. Body weight was an exploratory pharmacodynamic measure, not evidence from a trial designed and powered to establish weight-loss benefit.

The most discussed result came from the titration cohort of only eight participants:

• mean end-of-study weight change was -2.06%;
• four of eight maintained at least 5% weight loss at the end-of-study visit;
• responses varied, and two participants did not lose weight during the study.

Those numbers describe this cohort. Without placebo or an active comparator, they cannot separate a drug effect from normal weight fluctuation, study participation, behavior changes, regression to the mean, or other influences. They also cannot establish how TE-8105 compares with semaglutide, tirzepatide, or any other product.

The flat-dose cohort makes the danger of selective storytelling obvious: its mean weight increased by the end-of-study visit. Neither cohort is a clean efficacy experiment. Quoting the most favorable subgroup without the design context turns preliminary observation into advertising.

Quick answer: Did four of eight participants “respond”? Four maintained at least 5% weight loss in one uncontrolled cohort. That is a preliminary observation, not proof of a response rate readers should expect.

What adverse events were reported?

The reported treatment-related events were mainly gastrointestinal and were described as dose-dependent and consistent with the GLP-1 drug class. They included nausea, abdominal pain, constipation, and vomiting.

The authors reported treatment-related adverse events in 19 of 24 participants in the single-dose portion and 13 of 14 in the multiple-dose portion. No severe treatment-emergent adverse events, serious adverse events, study-drug discontinuations, or withdrawals due to adverse events occurred in these 38 participants.

That statement should not be converted into a personal risk estimate. With only 38 selected participants, the study has little ability to detect uncommon harms, characterize risks in excluded groups, or show what happens with longer exposure. “No serious events observed” and “serious events cannot occur” are entirely different claims.

Our broader guide to GLP-1 side-effect evidence explains why trial reports, regulatory labels, post-market reports, and online anecdotes answer different questions.

Why does the open-label design matter?

Open-label means participants and investigators knew TE-8105 was being given, and there was no control group to show what would have happened without it. This design can still characterize drug concentrations and identify common short-term tolerability problems. It is much weaker for subjective symptoms, behavior-sensitive outcomes, and efficacy.

The purpose of escalating early cohorts is cautious learning: observe exposure, tolerability, and signals that help researchers decide whether and how to continue development. It is not to deliver a definitive comparison.

The eligibility criteria also narrowed the sample. Participants were adults aged 18 to 65 who were overweight or obese, otherwise medically healthy, had stable weight, and did not have type 2 diabetes. Results should not be casually generalized to people with diabetes, significant comorbidities, different body-mass ranges, older adults, or long-term users.

For more context, see what entering Phase 1 actually means and Peptide Research Status Explained.

Who funded the study, and what conflicts were disclosed?

Immunwork funded the study, and several authors had financial or employment relationships with the sponsor and related companies. The paper states that five authors were Immunwork employees, two were also employees of T-E Meds, the principal investigator was contracted by Immunwork, and a scientific adviser was contracted by Immunwork.[^paper]

Sponsor involvement does not make results false. It does make transparent methods, complete reporting, independent replication, and disciplined interpretation especially important. Here, the limitations are visible: one site, small cohorts, no blinding, no comparator, narrow eligibility, and preliminary pharmacodynamic outcomes.

What evidence would change the conclusion?

Larger randomized controlled trials would be needed to establish whether TE-8105 has meaningful clinical value. Useful next evidence would include:

• prespecified weight and metabolic outcomes;
• placebo and, eventually, relevant active comparisons;
• enough participants to estimate common adverse events more reliably;
• longer follow-up for durability and delayed harms;
• broader populations that reflect intended clinical use; and
• independent confirmation of findings.

Until then, the defensible conclusion stays narrow: the trial characterized early human pharmacokinetics and short-term tolerability well enough to support further study. It did not establish superior efficacy, adherence, convenience, safety, or comparative benefit.

Frequently asked questions

Is TE-8105 a GLP-1 drug?

TE-8105 is an investigational GLP-1 receptor agonist. It has not acquired the approval status or evidence base of marketed GLP-1 medicines.

Was the TE-8105 trial placebo-controlled?

No. It was open-label and had neither placebo nor active comparator groups.

Can the 120-hour half-life support less-frequent administration?

It gives researchers a pharmacokinetic reason to study less-frequent subcutaneous administration. It does not prove that such use would be more effective, safer, easier, or preferred.

Does “well tolerated” mean TE-8105 is safe long term?

No. It summarizes observations in 38 selected participants during an early study. Rare and long-term harms require much larger and longer studies.

Where can I read the study?

The full paper is open access through PubMed Central and has DOI 10.1002/jcph.70224. The study record is NCT06471530.

---

This article is for general education and evidence literacy. It is not medical advice, treatment guidance, dosing guidance, sourcing guidance, purchasing guidance, or a recommendation to use or switch to TE-8105 or any GLP-1 product.

[^paper]: Polasek TM, Chen Y-S, White JD, et al. “First-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus.” Journal of Clinical Pharmacology. 2026;66(8):e70224. doi:10.1002/jcph.70224; PMID 42530137. [^registry]: ClinicalTrials.gov. “A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes.” NCT06471530.